Fig. 3. Effects of tirzepatide on kidney function and albuminuria.

a, Top: least-squares mean changes from baseline in eGFR plotted as a function of duration of treatment in participants randomized to tirzepatide (red circles) or placebo (black squares). Bottom: the estimated mean treatment difference in the change in eGFR with tirzepatide versus baseline compared with placebo plotted as a function of duration of treatment. b, The least-squares mean change in UACR in participants treated with tirzepatide (red) and placebo (black) as a function of duration of treatment. The error bars represent the s.e.m. for all panels; P values are two-sided for each time point comparison for a and b based upon comparing the least-squares means calculated from a mixed-model repeated-measures model incorporating baseline value, sex, history of HF decompensation within 12 months, diabetes status, baseline BMI group (<35, ≥35 kg m⁻²), treatment assignment, time, and treatment × time interaction. No correction was made for multiple hypothesis testing.